MLN8237

Background Information:

A potent, selective and orally bioavailable Aurora A Kinase inhibitor
with more than 200-fold selectivity against Aurora B Kinase, currently
in clinical trial.

Reference:

1. Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and
selective liquid chromatography/tandem mass spectrometry method for
determination of MLN8237 in human plasma. J Chromatogr B Analyt Technol
Biomed Life Sci. 2010 Sep 1;878(25):2369-73.
2. M. G. Manfredi, et al, Characterization of Alisertib (MLN8237), an
Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel
In Vivo Pharmacodynamic Assays, Clin Cancer Res, Dec 15, 2011, 17; 7614.
3. Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, Mueller I, Savory
WJ, Williams DH, Eyers PA. Drug-resistant aurora A mutants for cellular
target validation of the small molecule kinase inhibitors MLN8054 and
MLN8237. ACS Chem Biol. 2010 Jun 18;5(6):563-76.

APIM050202: MLN8237

CAS No.: 1028486-01-2.
Molecular Formula: C₂₇H₂₀ClFN₄O_4.
Molecular Weight: 518.9.
Purity: >98.5% (HPLC at 214 and 254 nm).
QC: HPLC, ¹HNMR and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0 °C (short term), -20 °C (long term), desiccated.